European Expansion: Five Questions US Life Sciences Investors Should Ask

Key Takeaways

• European expansion often becomes relevant well before commercial launch, particularly through clinical development, partnerships and licensing activities.

• A credible European strategy should identify what the company wants to achieve, where it intends to do it and how it plans to execute.

• IP, data and AI issues can affect the viability of an expansion strategy and may later become financing or transaction issues.

• Investors should assess European readiness before problems surface during a financing, strategic transaction or exit.

Why Should Life Sciences Investors Think About Europe Early?

For many US life sciences companies, Europe enters the picture gradually.

A clinical trial includes European sites. A collaboration with a European research institution is discussed. A licensing opportunity emerges. Eventually, management starts considering a more permanent European presence or commercial launch.

For investors, these developments raise a broader question: Is the company actually ready for Europe?

Europe remains both a major opportunity and a complicated environment in which to execute. The current debate within the European life sciences ecosystem illustrates that point. Europe continues to produce excellent science, talent and companies, but fragmentation and the practical challenges of scaling across multiple markets remain significant.

For a US portfolio company, the challenge is rarely deciding whether "Europe" is attractive in the abstract. The more useful question is whether the company has a realistic plan for operating there.

Here are five questions investors may want to ask.

1. What Does "Expanding into Europe" Actually Mean?

A credible European strategy should start with a specific objective rather than a general ambition to enter the European market.

"Europe" can mean very different things for different life sciences companies.

For an early-stage biotech, European expansion may initially mean clinical trial sites, investigators and research collaborations. For another company, it may mean licensing or partnering with European pharma. For a commercial-stage company, the objective may be market access, distribution or establishing its own European operations.

Geography matters as well.

Europe is not a single market in every practical respect. EU legislation harmonizes important areas, but differences remain in healthcare systems, reimbursement, employment, commercial practices and regulatory implementation. The UK and Switzerland add another layer.

Investors should therefore ask relatively basic questions early: What is the company trying to achieve in Europe? Which countries matter? Why those countries? What activities will actually take place there? And who will execute the strategy?

A plan that simply says "European expansion" probably needs another round of work.

2. Is the Company's IP Position Ready for Europe?

Investors should understand whether the company's IP ownership and licensing arrangements support the activities it intends to conduct in Europe.

Life sciences companies rarely build everything themselves. Their core technology may originate from a university. Research may be conducted with academic institutions or CROs. Product development may involve strategic partners. Key technology may be licensed rather than owned.

Each additional relationship can add another layer to the IP chain. 

Questions around background IP, improvements, publication rights, sublicensing, field restrictions and territorial rights may appear technical when an agreement is signed. They can become highly commercial once a company enters a financing, licensing or acquisition process.

Territorial scope deserves particular attention when Europe becomes relevant. Does an existing license actually provide the rights required for the contemplated European activities? Do collaboration agreements allocate newly developed IP clearly? Are there consent requirements or restrictions that could affect a future transaction?

A company does not need a perfect IP history. But it does need to know what it owns, what it licenses and whether those rights support the strategy investors are funding.

3. Can the Business Model Work Under European Data and AI Rules?

For data-driven life sciences businesses, regulatory questions should be tested against the business model rather than considered as a separate compliance exercise.

This is particularly relevant for digital health, diagnostics, health AI and data-intensive biotech businesses.

The practical questions are often straightforward. What data does the company need? Where does that data come from? Can the company use it for the intended purpose? Does data need to move between Europe and the United States? How is AI being used within the product or development process?

The GDPR remains central to many of these questions. The EU AI Act adds another layer for companies developing or deploying AI systems. 

For investors, however, the most useful question is not whether the company has produced a GDPR policy or an AI governance document. It is whether the European legal framework changes a material assumption underlying the business model. Finding that out before deployment is considerably easier than redesigning the model afterwards.

4. Would the Company Be Ready for European Due Diligence Tomorrow?

European issues that appear manageable during ordinary operations can become much more visible during a financing or strategic transaction.

A company may operate for years without anyone asking detailed questions about a particular university license, data transfer arrangement or collaboration agreement.

Then a financing round starts. Or a pharma company proposes a strategic partnership. Or an acquirer opens a data room. Suddenly, those issues matter.

Depending on the business, a European diligence process may scrutinize IP ownership, material licenses, data governance, AI use, cybersecurity, regulatory matters and key commercial agreements.

The important point for investors is not that every company must be legally perfect (very few are). The issue is whether management knows where the material risks are, has appropriate documentation and can explain how those risks are being managed. That is a much stronger position than discovering them for the first time during a transaction.

5. Is the Company Treating Europe as a Growth Market?

The legal and regulatory framework should inform a European growth strategy, not become the strategy itself.

US companies are often tempted to approach Europe through a long list of regulatory questions. GDPR. AI Act. Clinical trials. Medical device regulation. Employment. Corporate structure.

All of these may matter. But an expansion strategy built around compliance alone misses the larger point. Europe offers sophisticated healthcare markets, leading research institutions, established pharmaceutical clusters, clinical development capabilities and potential strategic partners.

The investor question should therefore remain commercial: Where can Europe create value for this company? The legal structure should follow from that answer.

Sometimes the right approach will be a European subsidiary. Sometimes a distributor, licensing partner or strategic collaboration will make more sense. Sometimes the right decision will be to postpone a broader European presence altogether.

There is no universally correct European expansion model. There should, however, be a commercial rationale behind the one being funded.

What Should Investors Take Away?

The European life sciences debate currently focuses heavily on scale.

That is understandable. Europe produces world-class science and companies but has historically struggled to provide the capital and market conditions required to scale them. Recent initiatives such as the European Life Sciences Coalition reflect the growing focus on closing that gap.

US investors looking at Europe from the perspective of their portfolio companies face a somewhat different challenge. Their companies often already have access to capital. The question is whether they can translate that capital, technology and ambition into a European strategy that actually works.

A few well-directed questions at board or investor level can reveal surprisingly quickly whether that strategy is ready. The earlier those questions are asked, the easier most issues are to address.